Business Wire

Vecima Acquires Falcon V Systems, Provider of Innovative Software Orchestration Platform for Cable, Fiber, and Mobile Access Networks

11.10.2024 13:30:00 CEST | Business Wire | Press release

Share

Combination of Vecima’s Entra Cloud™ and Falcon’s Principal Core and Test Suite will help operators accelerate and simplify cable, fiber, and mobile access network and service flow convergence, using automated software tools and testing Charter Communications will be the initial customer, signing a multi-year deal to deploy both the Principal Core and Test Suite Falcon V Systems’ open, interoperable platform supports multiple vendors’ vCMTS platforms, including Vecima’s Entra® vCMTS & Entra® vPON Manager

Vecima Networks, Inc. (TSX: VCM) today announced that, through its subsidiary Vecima Technology B.V., it has acquired Falcon V Systems, a Poland-based provider of vendor-agnostic, virtualized software solutions and services for Broadband Service Providers worldwide.

Vecima has acquired all outstanding Falcon V Systems shares, as well as the company’s technology, intellectual property, and talent. With the close of the acquisition today, Vecima will onboard a significant portion of the Falcon V team which will be integrated into Vecima’s Video & Broadband Solutions business, comprising its market-leading Entra broadband access portfolios and talent.

Falcon V Systems’ key products will be integrated into Vecima’s Entra Cloud™ portfolio of open, interoperable, cloud-native applications that help cable operators transform their networks for next-generation broadband access:

  • Falcon V Systems’ Principal Core manages across multiple cable, fiber, and mobile cores, allowing a multivendor environment, with seamless integration across the OSS/BSS ecosystem — a convergence of services not possible previously.

  • The Test Suite is a comprehensive set of tools, focused on helping Broadband Service Providers accelerate deployments and feature enhancements, through an automated, end-to-end test environment.

“I’m incredibly proud of what the Falcon V team has accomplished, and I extend my sincerest thanks to our talented Falcon team, our partners, and our customers,” said Ulf Andersson, CEO of Falcon V Systems. “Vecima will take our work forward and bring it to market on a global scale, unlocking the potential of the Falcon V technology and team.”

“Our work over the last several years with Falcon V Systems has been a critical component in our long-term access architecture strategy, enabling us to simplify and enhance the subscriber experience,” said Justin Colwell, Executive Vice President, Connectivity Technology, Charter Communications. “We plan to deploy the Principal Core, which will be a component of Vecima’s vCMTS solution, along with the Test Suite, and look forward to working closely with Vecima to lead wider adoption of the Entra Cloud platform across the industry.”

“Flexibility and interoperability are the cornerstone of Vecima’s unique approach to access networks and the hallmark of Falcon V Systems’ automation and orchestration software,” said Clay McCreery, Chief Operating Officer at Vecima. “With this acquisition, Vecima expands its research and development footprint into Europe with an expert team of DAA technologists in Poland. Falcon V Systems will be able to take advantage of Vecima’s global scale, existing vCMTS and PON platforms, and extensive customer relationships.”

“Vecima’s mission is to empower service providers globally with the transformative solutions that usher in the new multi-gigabit connectivity era to come,” said Sumit Kumar, Vecima President and Chief Executive Officer. “We are embarking on a new phase of growth, and by adding the Falcon V Systems team and technology to our expansive industry-leading broadband access portfolio, we broaden, once more, our ability to meet the evolving network convergence needs of Broadband Service Provider customers worldwide. With the Falcon team & Charter’s long-term partnership, this acquisition further deepens Vecima’s leadership in the Broadband Service Provider segment.”

About Falcon V Systems

Falcon V Systems is an independent challenger that delivers a cost-effective, scalable, and non-proprietary open DAA solution for Broadband Service Providers based on Software Defined Networking (SDN) and Network Functions Virtualization (NFV). This non-monolithic, agile architecture will enable more efficient use of network assets, data centers, and cloud assets. Thanks to open interfaces, the solution evolves along with the growth of needs and supports the cooperation between operators and other vendors.

About Vecima Networks

Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words “believes”, “may”, “plans”, “will”, “anticipates”, “intends”, “could”, “estimates”, “expects”, “forecasts”, “projects” and similar expressions, and the negative of such expressions.

Forward-looking information in this news release includes, but is not limited to, any statements respecting: Vecima will onboard a significant portion of the Falcon V team which will be integrated into Vecima’s Video & Broadband Solutions business; closing of the transaction will allow Vecima to expand its research and development footprint into Europe; Falcon V Systems’ key products will be integrated into Vecima’s Entra Cloud™ portfolio; Charter Communications’ plans to deploy the Principal Core and Test Suite.

The forward-looking statements are based on the current expectations of the management of Vecima and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated.

A more complete discussion of the risks and uncertainties facing Vecima is generally disclosed under the heading “Risk Factors” in the Company’s Annual Information Form dated September 19, 2024, as well as the Company’s continuous disclosure filings with Canadian securities regulatory authorities available at www.sedarplus.ca. All forward-looking information herein is qualified in its entirety by this cautionary statement, and Vecima disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events, or developments, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241010671688/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye